Search - tctmd.com

Displaying 21 - 40 of 171

Sort: Relevancy | Date

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

News Daily News

Large Meta-analysis Confirms Survival, Bleeding Benefits With Radial Access

Michael O'Riordan

February 05, 2021

News Daily News

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

Shelley Wood

January 07, 2021

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Opinion CV Team Dispatch

March 2020 News Roundup

L.A. McKeown

March 12, 2020

News Daily News

SCAI Experts Update Transradial Guidance

Yael L. Maxwell

January 03, 2020

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Industry News

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

May 23, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Advertisement

Observational Study Supports Continuing Oral Anticoagulation During PCI

Large Meta-analysis Confirms Survival, Bleeding Benefits With Radial Access

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

March 2020 News Roundup

SCAI Experts Update Transradial Guidance

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

TCTMD’s Top 10 Most Popular Stories for May 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content